Executive Leadership

USA Team

Yuelei Shen, Ph.D.
Chairman of the Board, President and CEO

Dr. Yuelei Shen is the founder, President and CEO of Beijing Biocytogen Co., LTD. Dr. Shen received his Ph.D. from the University of Massachusetts Medical School in 2004. He performed his postdoctoral training under Dr. Dan R. Littman in New York University School of Medicine from 2003-2008. In 2008, Dr. Shen founded Biocytogen in Worcester, MA and in 2009, he moved back to Beijing, China and established Beijing Biocytogen Co., LTD. In 2015, Biocytogen Jiangsu Co., Ltd was established, and in 2018, Biocytogen Boston Corporation began operations in Wakefield, MA. In the past 10 years, Biocytogen has transformed from a business that solely provides custom gene-targeted models to one that offers a comprehensive set of Immuno-Oncology (I/O) and antibody development platforms. These platforms cover innovative animal model generation, large scale production, pharmacology studies and therapeutic antibody discovery services. Our chief goal is to promote drug discovery more efficiently.

Chaoshe Guo, Ph.D., M.D.
Vice President (Global Head of Business Development)

Dr. Guo graduated from University of Goettingen & Max-Planck-Institute of Biophysical Chemistry, Germany and received a doctoral degree in Biochemistry in November, 2003, where he worked on the functional study of molecular chaperones via biochemistry, structural biology, and gene knockout mouse models. In 2005-2013, Dr. Guo has focused on cardiovascular and blood system development in Boston Children’s Hospital/Harvard Medical School. His research has been published in JCI, Development, and other highly reputed journals. Dr. Guo is experienced in animal model generation and phenotype analysis. In October, 2013, Dr. Guo served as the Senior R&D Director and Key Account Manager of Beijing Biocytogen Co., Ltd, to help the company establish CRISPR based gene editing platform and marketing promotion, and also got involved in humanized immune checkpoint animal model generation. Since June 2015, Dr. Guo served as the Vice President of Marketing and Global Head of Business Development.

Qingcong Lin, Ph.D.
CEO of Biocytogen Boston Corporation

Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation. Dr. Lin focuses on Biocytogen’s global business development for antibody discovery services, RenMab/RenLite licensing and therapeutic antibody co-development, and on providing gene targeting services and humanized mouse models for in vivo efficacy and toxicity assessments of immuno-oncology antibody candidates. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received a Ph.D. from Albert Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.

Benny Yang, Ph.D.
Chief Scientific Officer and Senior Director of New Drug Development

Dr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from University of Connecticut Health Center (UCHC) and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor at the Department of Microbiology and Immunology. In 2016, he joined Biocytogen and has been leading the antibody drug discovery.

Zhaoxue (Luke) Yu, Ph.D.
Deputy General Manager & Global Head of Preclinical Pharmacology

Dr. Zhaoxue (Luke) Yu joined Biocytogen as Global Head of Preclinical Pharmacology in 2020. Dr. Yu brings more than 15 years of research and technical leadership experience in drug discovery and development for immune/autoimmune diseases, oncology, neurological diseases, ocular diseases and metabolic diseases across various therapeutic modalities including antibodies, biologics, small molecules, mRNAs, and AAVs. Prior to Biocytogen, Dr. Yu served as a pharmacology technical leader at Gemini Pharmaceuticals, Achillion Pharmaceuticals, and Alexion Pharmaceuticals. Dr. Yu has been a major contributor to multiple drug development programs from preclinical to clinical stages, some of which have subsequently obtained success approvals by the FDA. Dr. Yu received his Ph.D in Neurobiology and M.D. in China. He has held postdoctoral research positions at institutions including Emory University, Yale University, and Harvard Boston Children’s Hospital.

James Jin, Ph.D.
Vice President of Biocytogen Boston Corporation

Dr. James Jin received his PhD of virology at Wuhan University in 1997. He had his postdoctoral training at Colorado State University. He worked as a research assistant professor in University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a senior scientist. Dr. Jin joined Biocytogen as the director of technology in 2011, and then was promoted to vice president in 2012. His research covers virology, immunology, proteomics, protein structure, human stem cell, and gene-targeting animal model.

China Team

Yan Zhu, EMBA
Vice President of Operations

Yan Zhu joined Beijing Biocytogen in 2011, and she currently serves as the Vice President of Operations. Ms. Zhu is responsible for the company’s overall operations, such as research and development (R&D), production, services, human resources and general support. Ms. Zhu has more than 10 years of experience in clinical practices; she has been engaged in research and development management, project investment, operation management and sales in the biomedical industry for nearly 20 years. Ms. Zhu holds an EMBA from Tsinghua University and a bachelor’s degree from the Harbin Medical University (both in China).

Bin Liu,
Chief financial officer

Mr. Liu Bin has been our chief financial officer since May 2020. He was the financial controller at ABB Xi’an Power Capacitor Co., Ltd. from March 2003 to April 2007. He was the chief financial officer at Shiji Tianle Wholesale Asset Porfolio from June 2010 to January 2016,and also at Xinjiang Keda Julong Equity Investment Partnership. He was also the vice president of finance of Hitevision Co., Ltd. ,a company listed on the Shenzhen Stock Exchange (stock code: 002955), from December 2018 to December 2019. Mr. Liu obtained a bachelor’s degree in applied mathematics in June 1990 from Huazhong University of Science and Technology in the PRC. He also obtained a Master of Science degree from the University of Akron in the United States in August 1995. In August 1998, he obtained a master’s degree in business administration from the Arizona State University in the United States and a master’s degree in international management from the Thunderbird School of Global Management (formerly known as the American Graduate School of International Management) in the United States.

Yongliang Wang,
Deputy general manager

Mr. Wang Yongliang joined our Group in July 2017. He has been our deputy general manager since July 2021 and our chief secretariat officer since December 2020. Mr. Wang worked at SinoChem Group from August 2010 to February 2014. From February 2014 to September 2015, he was a senior investment manager of China SDIC High-tech Industry Investment Corporation, formerly known as China High-tech Investment Group whose wholly-owned subsidiary HighTech Investment Development Co., Ltd. was an investor shareholder of our Company. He was also a senior investment manager, vice president and deputy investment director of Harvest Investment Management Co., Ltd. from October 2015 to July 2017. Since July 2017, he has served as an assistant to the chairman of the Board of our Company. Mr. Wang was awarded a Bachelor of Science degree with chemistry as his major from Nankai University in the PRC in June 2007. In June 2010, he obtained a Master of Science degree with macromolecular chemistry and physics as his major from Nankai University in the PRC.

Dirui Li, Doctor
Director of Pharmacology

Dirui Li received his PhD from College of Veterinary Medicine, China Agricultural University in 2012 (majoring in veterinary biomedicine) and research focused on infection and Immunology & Recombinant Vaccines; Then he did postdoc research at China Agricultural University and Uppsala University, Sweden. In 2016, he returned to China to join Biocytogen Pharmaceuticals (Beijing) Co., Ltd, successively served as Senior Scientist of Gene Editing Department, Manager of Pharmacological Department and Senior Manager of SD Department, currently served as the head of Pharmacology Department(Beijing/Haimen), and developed the pharmacological platform (biomarker, drug metabolism, toxicological pathology detection platform) for Pharmacology Department.


Haichao Zhang, Ph.D.
Operation Director of Haimen (Jiangsu) Animal Center

Dr. Zhang joined Beijing Biocytogen in 2010. Since 2016, Dr. Zhang has served as the Operation Director of Biocytogen Haimen (Jiangsu) Animal Center. In the past, Dr. Zhang has worked as the Director of Molecular Biology and the Director of Marketing. Dr. Zhang holds a Ph.D. from the China Pharmaceutical University and a bachelor’s degree in Biochemistry from the Hebei Normal University (both in China).


Jiawei Yao, Ph.D.
Director of Gene Editing

Dr. Yao received a bachelor of science in Bioengineering from Tianjin University of Technology, a master’s degree in Biochemtry from the Tianjin University, and holds a Ph.D. in Pharmaceutical Engineering from the Tianjin University. Dr. Yao currently serves as the Director of the Gene Editing who oversees the research and development (R&D) of gene targeting.

Rong Chen
Rong Chen, MD, Ph.D.
CEO and CMO of Eucure Biopharma

Dr. Chen Zhaorong has been our deputy general manager. He has also been the chief medical officer of Eucure (Beijing) since June 2021. Dr. Chen was the representative of Sanofi China and the vice president of GlaxoSmithKline China. He also worked as the chief medical officer of CASI Pharmaceuticals, Inc, a biopharmaceuticals company listed on NASDAQ (stock code: CASI). From November 2016 to December 2017, he served as the chief medical officer of Phagelux (Nanjing) Biotechnology Co., Ltd. He was also the chief medical officer of Chime Biologics (Wuhan) Co., Ltd, formerly known as Xikang (Wuhan) Biopharmaceutical Co., Ltd., from January 2018 to January 2020, and Shanghai Langyu Health Technology (Group) Co., Ltd. Dr. Chen obtained a bachelor’s degree in medicine in August 1983 and a master’s degree in pharmacology in October 1985 from Shandong Medical University (formerly known as Shandong Medical College) in the PRC. In May 1989, he obtained a doctorate degree in philosophy from the University of Adelaide in Australia.

Sabrina Wang
Sabrina Wang, EMBA
Deputy General Manager and Chief Operation Officer

Ms. You Wang has been the deputy general manager since December 2020, and the chief operation officer of Eucure (Beijing) since October 2019.

From May 2004 to May 2012, Ms. Wang was a laboratory assistant, project coordinator, senior project coordinator, associate project manager, project manager, associate business development manager and business development manager of Q Squared Solutions (Beijing) Co., Ltd. She was also the Asia Regional Pre-Analytical Services and Investigator Manager at Q Squared Solutions (Singapore) Co., Ltd. between May 2012 and July 2013. From July 2013 to July 2014, she held the role of associate business development director at IQVIA China. From September 2014 to August 2018, she served at Paraxel China Co., Ltd. as she was the director of business development, head of business development in China, and senior director of portfolio management. From September 2018 to October 2019, she was the head of Biotech Delivery Unit at IQVIA China.

Zhihong Li
Zhihong Li, Ph.D.
Deputy General Manager and Chief Regulatory and Strategy Officer

Dr. Zhihong Li has been the deputy general manager of our Company since December 2020, and our chief regulatory and strategy officer of the Eucure (Beijing) since March 2019. Dr. Li has clinical development and review experience in several therapeutics areas including oncology. He worked at Pfizer Inc., and was as staff fellow at Food and Drug Administration of the United States from May 2009 to December 2007. Dr. Li obtained a bachelor’s degree and a master’s degree in pharmacy in July 1992 and in June 1995 respectively from Beijing Medical University in the PRC. In March 2007, he obtained a doctor of philosophy degree from the University of Minnesota in the United States.

Back to top